Positive 1b Data For Mastocytosis Therapy Announced By Major Biotech Company

Cogent Biosciences Unveils Positive Data from SUMMIT Trial of Bezuclastinib in Nonadvanced Systemic Mastocytosis Patients.

Disclaimer: The information in this article is accurate as of the time of writing. However, the situation may change rapidly, and all users are advised to consult with a healthcare professional for the most up-to-date and accurate information.

In a significant development for the biotech industry, Cogent Biosciences has announced positive Part 1b data fr…